Navigation Links
Eqalix Enters Sponsored Research Agreement with Temple University
Date:12/11/2012

Philadelphia institutions for several groundbreaking technologies being developed in the fields of aesthetic dermatology, the consumer market for beauty and skin care, acute and chronic wounds requiring skin replacement, vascular replacements and the repair of traumatic damage to peripheral nerves.

Eqalix plans to leverage these technologies to develop and commercialize: a) plant protein-based nano-fiber scaffolds for use in aesthetic dermatology and wound healing markets; b) small-diameter hybrid vessels that reduce graft thrombogenicity and promote the creation of a functional endothelium after implantation; and c) three-dimensional tissue scaffolds with tunable properties for tissue and organ replacement and repair.

The technologies move the bar higher and intend to replicate the function of damaged, diseased or aging tissues by providing “implants” or scaffolds that are non-immunogenic, bio-compatible, and intended to restore the features and function of the damaged tissue by using the body’s own repair mechanisms. Eqalix is attempting to create skin without scarring and contraction, blood vessels without clotting, repair of injured nerves and organ beyond current capabilities.

“These lofty goals, although seemingly futuristic, are in the immediate realm of scientific possibilities today --- and at Eqalix,” said Connell.

Temple’s new bioengineering department was established in January 2012. Housed in the College of Engineering, Temple’s fastest growing college, the department seeks to provide a well-rounded, in-depth education and a world-class research experience at the interface of engineering, the life sciences and medicine, with the goal of promoting scientific discovery, as well as the development of new technologies that will benefit humanity.

Eqalix, Inc. is a privately held Virginia based
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
2. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
3. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
4. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
5. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
6. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
7. Centers for Medicare & Medicaid Services Win 2012 National Cybersecurity Innovation Award
8. Nu Skin Enterprises Enters Into Agreement To Acquire NOX Technologies
9. Cell Therapeutics Reports on Cooperative Group Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
10. Wolters Kluwer Research Now Available via Bloomberg Tradebook
11. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , ... September 01, 2015 , ... In her thought ... transports the reader to a not-so-distant future faced with an Ebola pandemic that is ... who overcomes personal tragedy to enter the world of counterterrorism, and who continues to ...
(Date:9/1/2015)... Boston, MA (PRWEB) , ... September 01, 2015 ... ... from top biopharmaceutical companies in the neuro and pain management space join prominent ... Joseph B. Martin Conference Center at Harvard Medical School in Boston. , ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new host-based therapy ... at the Keck Graduate Institute and its collaborators. The discovery has the potential ... published online on August 27 by Scientific Reports, an open access research journal ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Global ... chain risk management and resiliency practitioners with luminaries and thought leaders to advance ... be recognized for their innovations and performance excellence. At that time its principle ...
Breaking Biology Technology:Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3
... , , , 7.6.4 Long PCR , ... as desired with every temperature , command, enables a , ... , With Long PCR, this function can be used ... elongation. , , ...
... , , , , , ... set of conditions that can be applied to all PCR amplifications. For ... used, the annealing temperatures , of the PCRs can differ ... stringent annealing temperature is a prerequisite for reliable results , ...
... , , , , ... fragment using the PCR* are an everyday occurrence in the lab. For example, , ... which hinder, , or even prevent, further analyses (cycle ... of the PCR result. In such cases, PCR , ...
Cached Biology Technology:PCR Optimization 2PCR Optimization 3Using Gradient PCR to determine the optimum annealing temperature. 2
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/5/2015)... , August 5, 2015 According ... Access Management Market by Software, Services, Vertical (BFSI, Airport, IT ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Market globally into various segments. The global PIAM Market ... to $546.2 Million by 2019, at a CAGR of ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... acetyl CoA carboxylase 2,or ACC2, appears to turn the ... in part why the animals can eat more and ... Medicine,researchers.,The report that appears online today in the Proceedings ... cells in these mice bred to lack ACC2," said ...
... University,of California, San Diego have invented a process ... of specialized cells being sought as possible,treatments for ... and Shu Chien, UCSD bioengineering professors, and Christopher,J. ... in a paper published in the February issue ...
... have discovered a way to overcome one of the ... kill normal cells in the,process of eradicating cancer cells.,In ... of the Proceedings of the,National Academy of Sciences (PNAS), ... into a specially designed,virus. The virus eradicated prostate cancer ...
Cached Biology News:Lack of enzyme turns fat cells into fat burners 2Priming embryonic stem cells to fulfill their promise 2Priming embryonic stem cells to fulfill their promise 3Columbia research lifts major hurdle to gene therapy for cancer 2